RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Bill Would Restrict Co-Pays, Other Cost-Sharing Measures

Bill Would Restrict Co-Pays, Other Cost-Sharing Measures

Posted 20 March 2012

Co-pays, cost-sharing, coinsurance and other methods used by pharmaceutical companies as an incentive for patients to purchase their drugs would be restricted under a new bipartisan bill introduced in the House of Representatives on 19 March.

H.R. 4209 - Patient's Access to Treatments Act of 2012, introduced by Reps. David McKinley (R-WV), Lois Capps (D-CA), Barney Frank (D-MA), Henry Cuellar (D-TX) and C.W. Bill Young (R-FL), would do away with preferential treatment of brand-name pharmaceutical products.

"A group health plan, or a health insurance issuer offering group or individual health insurance, that provides coverage for prescription drugs and uses a formulary or other tiered cost-sharing structure shall not impose co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier that exceed the dollar amount (or its equivalent) of co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a non-preferred brand drug tier (or prescription drugs in a brand drug tier if there is no non-preferred brand drug tier)," says the bill.

The payments are widely used now, particularly by companies looking to keep generic competition at bay. Some co-payment assistance plans make the brand-name out-of-pocket cost to the consumer lower than it would be for a generic product, thereby influencing the consumer to ask for the brand-name product.

Critics have charged this unnecessarily inflates healthcare spending, while pharmaceutical companies have countered by saying it decreases costs for the patient.


Read more:

H.R. 4209 - Patient's Access to Treatments Act of 2012

 

© 2022 Regulatory Affairs Professionals Society.